- A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS
- Study of Arimoclomol in Inclusion Body Myositis (IBM)
- Arimoclomol in Sporadic Inclusion Body Myositis
- Arimoclomol in Amyotropic Lateral Sclerosis
- A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C
- A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS
- Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial
- Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C
- Early Access Program With Arimoclomol in US Patients With NPC
- Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
- Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial
- Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis
All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.